An Observational Study of OZURDEX® in Diabetic Macular Edema (DME)
NCT ID: NCT02188173
Last Updated: 2016-06-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
200 participants
OBSERVATIONAL
2014-07-31
2016-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Ozurdex for Treatment of Recalcitrant Diabetic Macular Edema
NCT01571232
Retrospective Data Collection Study in Patients With Macular Oedema Receiving OZURDEX®
NCT02181530
Retrospective Trial on the Efficacy and Safety of Intravitreal Ozurdex in Patients With Diabetic Macular Edema.
NCT02121197
A 3-Month Clinical Trial to Assess the Safety and Efficacy of the OZURDEX® Intraocular Implant in Patients With Diabetes Mellitus
NCT01673191
Study of OZURDEX® in the Treatment of Diabetic Macular Oedema (DME) in Australia - The AUSSIEDEX Study
NCT02731911
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
dexamethasone 700 ㎍ intravitreal implant
Patients who receive dexamethasone 700 ㎍ (OZURDEX®) intravitreal implant treatment for Diabetic Macular Edema. All decisions regarding treatment are made at the sole discretion of the treating physician in accordance with their usual practices.
dexamethasone 700 ㎍ intravitreal implant
Patients who receive dexamethasone 700 ㎍ (OZURDEX®) intravitreal implant treatment for Diabetic Macular Edema. All decisions regarding treatment are made at the sole discretion of the treating physician in accordance with their usual practices.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
dexamethasone 700 ㎍ intravitreal implant
Patients who receive dexamethasone 700 ㎍ (OZURDEX®) intravitreal implant treatment for Diabetic Macular Edema. All decisions regarding treatment are made at the sole discretion of the treating physician in accordance with their usual practices.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Allergan
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical Director
Role: STUDY_DIRECTOR
Allergan
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Retinal Consultants of Phoenix
Phoenix, Arizona, United States
West Coast Retina
San Francisco, California, United States
Orange Co Retina Medical Group
Santa Ana, California, United States
Bay Area Retina Associates
Walnut Creek, California, United States
Colorado Retina Associates
Denver, Colorado, United States
Illinois Retina Associates
Harvey, Illinois, United States
Raj Maturi, MD PC
Indianapolis, Indiana, United States
John-Kenyon American Eye Institute
New Albany, Indiana, United States
Associated Retina Consultants
Royal Oak, Michigan, United States
Associated Retinal Consultants, PC
Traverse City, Michigan, United States
Lifelong Vision Foundation
Chesterfield, Missouri, United States
Eyesight Ophthalmic Services
Portsmouth, New Hampshire, United States
New Jersey Retina
New Brunswick, New Jersey, United States
Long Island Vitreoretinal Consultants - Long Island Retina - Hauppauge
Great Neck, New York, United States
Mid Atlantic Retina
Philadelphia, Pennsylvania, United States
Texas Retina Associates, Arlington
Arlington, Texas, United States
Valley Retina Institute, P.A.
McAllen, Texas, United States
Medical Center Ophthalmology Associates
San Antonio, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
REINFORCE
Identifier Type: OTHER
Identifier Source: secondary_id
GMA-US-EYE-0272
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.